Profectus Biosciences

Latest Headlines

Latest Headlines

Baltimore's Profectus BioSciences starts PhI trial of Ebola vaccine

Back in October 2014, Profectus BioSciences scored $9.5 million in Department of Defense funding to manufacture its trivalent vaccine to protect against Ebola and Marburg viruses. Now, the Baltimore-based biotech is taking its Ebola candidate to Phase I trials.

Ebola roundup: J&J; invests $200M in R&D;, Glaxo says vaccine will come too late

As the Ebola outbreak continues with deadly momentum, drugmakers are working at lightning speed to develop a vaccine.

Profectus immunizes first patient in Ph1 HIV vax trial

Baltimore-based Profectus Biosciences has inoculated its first patient in a Phase I trial of its multi-antigen DNA HIV vaccine. The study will monitor 60 HIV patients who are on stable